Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Effects of growth hormone treatment on glucose metabolism in idiopathic short stature

특발성 저신장증 환자에서 성장 호르몬 투여가 당 대사에 미치는 영향

  • Kwon, Seung Yeon (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Kim, Duk-Hee (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Kim, Ho-Seong (Department of Pediatrics, Yonsei University College of Medicine)
  • 권승연 (연세대학교 의과대학 소아과학교실) ;
  • 김덕희 (연세대학교 의과대학 소아과학교실) ;
  • 김호성 (연세대학교 의과대학 소아과학교실)
  • Received : 2006.02.17
  • Accepted : 2006.03.27
  • Published : 2006.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : To study the effects of growth hormone(GH) treatment on glucose metabolism and insulin resistance in children with idiopathic short stature(ISS). Methods : Glucose and insulin concentrations were measured during oral glucose tolerance test (OGTT) before and after GH treatment(0.6-0.7 IU/kg/week) in 20 patients with ISS. Insulin resistance was assessed by homeostasis model assessment(HOMA). Results : During OGTT, the mean blood glucose level did not show any significant changes after GH treatment. However, mean blood insulin levels of fasting and 30 minutes of OGTT showed significant increases after GH treatment, accompanying significant increases of insulin resistance. There was no difference in change of glucose, insulin levels and insulin resistance before and after GH treatment between two groups of body mass indices(BMI) of 25< and >25. There also was no significant difference between two groups of with and without family histories of diabetes mellitus (DM). There was no case of newly developed impaired glucose tolerance, fasting glucose tolerance, nor newly developed DM. Conclusion : GH treatment with doses of 0.6-0.7 IU/kg/week for mean 9.6 months in patients with ISS did not show any significant changes in blood glucose levels during OGTT. However, GH treatments induced considerably higher fasting insulin levels compared to pretreatment, resulting in statistically higher insulin resistance. Higher BMI and family history of DM did not induce any significant changes in glucose, insulin level and insulin resistance after GH treatment than the other groups.

목 적 : 성장 호르몬은 탄수화물 대사에 항 인슐린 작용을 나타내어 혈당을 상승시키는 작용을 하는 것으로 알려져 있으며, 최근 성장 호르몬 결핍이 없는 환자에서의 성장 호르몬 투여로 인한 초 생리적 농도의 성장 호르몬 투여가 당 항상성 및 인슐린 저항성의 변화를 초래하리라는 우려가 생기고 있다. 저자들은 특발성 저신장증으로 진단 받은 환아들을 대상으로 성장 호르몬 투여 전후에 경구 당 부하검사 및 인슐린 농도 검사를 시행하여 성장 호르몬 투여가 당 대사 및 인슐린 저항성에 미치는 영향에 대하여 알아보고자 하였다. 방 법 : 특발성 저신장증으로 진단되어 성장 호르몬 치료를 시작한 환아 20명에서 성장 호르몬 투여(0.6-0.7 IU/kg) 전후에 경구 당 부하 검사 및 인슐린 농도 검사를 시행하여 혈당, 인슐린 농도의 변화 및 인슐린 저항성의 변화를 분석하였다. 또한 비만 및 당뇨병의 가족력 유무에 따른 집단간의 혈당, 인슐린 농도 및 인슐린 저항성의 변화를 분석하였다. 결 과 : 성장 호르몬 투여 전후의 경구 당 부하 검사 결과 공복, 당 부하 30분 및 2시간의 혈당은 치료 전과 비교하여 의미있는 변화를 보이지 않았으나(P>0.05), 공복 및 당 부하 30분 인슐린 농도 및 인슐린 저항성은 성장 호르몬 투여 후에 투여 전보다 의미 있게 증가하였다(P=0.0001, P=0.02, P=0.01). 비만과 당뇨병의 가족력을 가진 환아들에서 성장 호르몬 투여 전후의 혈당, 인슐린 농도 및 인슐린 저항성의 변화량은 대조군과 유의한 차이를 보이지 않았다(P>0.05). 결 론 : 특발성 저신장증 환아 20명에게 평균 9.6개월 동안 성장 호르몬을 투여(0.6-0.7 IU/kg/week)한 후 분석한 결과, 성장 호르몬 투여가 혈당의 의미 있는 증가를 초래하지 않았으나, 인슐린 농도 및 인슐린 저항성을 증가시킴을 알 수 있었다. 비만이나 당뇨병의 가족력은 혈당, 인슐린 농도 및 인슐린 저항성의 변화량에 유의한 차이를 나타내지 않았으며, 향후 이에 대한 더 많은 표본수와 장기간의 추적 관찰이 필요할 것으로 생각된다.

Keywords

References

  1. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for growth hormone use in adults and children-2003 update. Endocr Pract 2003;9:64-76 https://doi.org/10.4158/EP.9.1.64
  2. Quigley CA, Gill AM, Crowe BJ, Robling K, Chipman JJ, Rose SR, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab 2005;90:5502-4 https://doi.org/10.1210/jc.2005-1676
  3. Moller N, Jorgensen JO, Abildgard N, Orskov L, Schmitz O, Christiansen JS. Effects of growth hormone on glucose metabolism. Horm Res 1991;36 Suppl 1:32-5
  4. Sharp PS, Beshyah SA, Johnston DG. Growth hormone disorders and secondary diabetes. Baillieres Clin Endocrinol and Metab 1992;6:819-28 https://doi.org/10.1016/S0950-351X(05)80168-5
  5. Reinauer H, Home PD, Kanagasabapathy AS, Heuk C. Laboratory diagnosis and monitoring of diabetes mellitus 2002. World Health Organization, 2002;16
  6. Bareille P, Azcona C, Matthews DR, Conway GS, Stanhope R. Lipid profile, glucose tolerance and insulin sensitivity after more than four years of growth hormone therapy in non-growth hormone deficient adolescents. Clin Endocrinol 1999;51:347-53 https://doi.org/10.1046/j.1365-2265.1999.00765.x
  7. Kemp SF. Growth hormone treatment of idiopathic short stature : History and demographic data from the NCGS. Growth Horm IGF Res 2005;15 Suppl A:S9-12 https://doi.org/10.1016/j.ghir.2005.06.004
  8. Rudman D, Kutner MH, Blakston RD, Cushman RA, Bain RP, Paterson JH. Children with normal-variant short stature : treatment with human growth hormone for six months. N Engl J Med 1981;305:123-31 https://doi.org/10.1056/NEJM198107163050302
  9. The Endocrine Society. Safety and efficacy of growth hormone treatment for idiopathic short stature. J Clin Endocrinol Metab 2005;90:5502-4 https://doi.org/10.1210/jc.2005-1676
  10. Hintz RL. Growth hormone treatment of idiopathic short stature : Clinical studies. Growth Horm IGF Res 2005;15 Suppl A:S6-8 https://doi.org/10.1016/j.ghir.2005.06.003
  11. Bryant J, Cave C, Milne R. Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev 2003:1-27
  12. Willhaus J. Growth hormone therapy and children with idiopathic short stature : A viable option- Pediatr Nurs 1999; 25:662-5
  13. Schwartz J, Carter C. Effects of growth hormone on glucose metabolism and glucose transport in 3T3-F442A cells : dependence on cell differentiation. Endocrinology 1988;122: 2247-56 https://doi.org/10.1210/endo-122-5-2247
  14. Salomon F, Sonksen PH. Physiological role of growth hormone in adult life. Acta Paediatr Scand Suppl 1987;337:158- 63
  15. Seminara S, Merello G, Masi S, Filpo A, Cauza F, D'Onghia G, et al. Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency. Clin Endocrinol 1998;49:125-30 https://doi.org/10.1046/j.1365-2265.1998.00502.x
  16. Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M, et al. Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age. Clin Endocrinol 2001;54: 243-51 https://doi.org/10.1046/j.1365-2265.2001.01178.x
  17. Yuen K, Cook D, Ong K, Chatelain P, Fryklund L, Gluckman P, et al. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults. Clin Endocrinol 2002;57:333-41 https://doi.org/10.1046/j.1365-2265.2002.01601.x
  18. Teunenbroek A, Keizer-Schrama M, Aanstoot HJ, Stijnen T, Hoogerbrugge N, Drop SL. Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Metabolism 1999;48: 7-14 https://doi.org/10.1016/S0026-0495(99)90003-3
  19. Sas T, Waal W, Mulder P, Houdijk M, Jansen M, Reeser M, et al. Growth hormone treatment in children with short stature born small for gestational age:5-years results of randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 1999;84:3064-70 https://doi.org/10.1210/jc.84.9.3064
  20. Sas T, Muinck S, Aanstoot HJ, Stijnen T, Drop S. Clinical metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated in girls with once or twice daily growth hormone injections. Clin Endocrinol 2000;52:741-7 https://doi.org/10.1046/j.1365-2265.2000.01007.x
  21. Al-Shoumer KA, Gray R, Anyaoku V, Hughes C, Beshyah S. Effects of four years' treatment with biosynthetic human growth hormone on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol 1998;48:795-802 https://doi.org/10.1046/j.1365-2265.1998.00460.x